Sarcoma  >>  sitravatinib (MGCD516)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sitravatinib (MGCD516) / BeiGene
AAAQ8661, NCT02978859: Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas

Active, not recruiting
2
29
US
MGCD516, Sitravatinib
Matthew Ingham, Mirati Therapeutics Inc.
Liposarcoma, Metastatic Liposarcoma
01/23
01/23

Download Options